Post-operative radiochemotherapy in patients with gastric cancer: One department's experience of 56 patients

British Journal of Radiology

Volumn 84, Issue 1001, 2011, Pages 457-463

  Spych, Michal ^a,b   Serbiak, B ^a,b   Rychter, A ^b   Jesien Lewandowicz, E ^a,b   Gottwald, L ^a   Fijuth, J ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENT DISEASE; RETROSPECTIVE STUDY; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 79955106465     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/25406515     Document Type: Article

References (29)

1. Kim JP, Kim YW, Yang HG, Noh DY. Significant prognostic factors by multivariate analyses of 3,926 gastric cancer patients. World J Surg 1994;18:872-8.
2. Kajiyama Y, Tsurumaru M, Udagawa H, Tsutsumi K, Kinoshita Y, Ueno M, et al. Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. J Clin Oncol 1997;15:1015-21.
3. Gunderson LL. Gastric cancer - patterns of relapses after surgical resection. Semin Radiat Oncol 2002;12:150-61. (Pubitemid 34522351)
4. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, et al. A randomized study comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990;8:1362-9. (Pubitemid 20252308)
5. Estape J, Grau JJ, Lcobendas F, Curto J, Daniels M, Vinolas N, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer: a 20-year follow-up. Ann Surg 1991;213:219-21.
6. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group Study. Ann Surg 1995;2:488-94.
7. Lise M, Nitti D, Marchet A, Sahmoud T, Duez N, Fornasiero A, et al. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann Surg Oncol 1995;2:495-501.
8. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, et al. A randomized trial comparing adjuvant fiuorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990;8:1362-9. (Pubitemid 20252308)
9. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7. (Pubitemid 23228247)
10. Earle CC, Marcun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-64. (Pubitemid 29339187)
11. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2001;12:1178-80.
12. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy of chemotherapy in resectable gastric cancer: five year follow-up. Lancet 1994;343:1309-12.
13. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-34.
14. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
15. Macdonald JS, Smalley S, Benedetti J. SWOG; ECOG; RTOG; CALGB; NCCTG. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction: update of the results of intergroup study INT-0116 (SWOG 9008). San Francisco: ASCO, 2004.
16. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-85. (Pubitemid 41628018)
17. Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer 2004;91:11-17. (Pubitemid 39013038)
18. Bora H, Unsal D, Akmansu M. Results of chemoirradiation after curative resection of locally advanced gastric cancer. Int J Clin Pract 2004;58:451-6. (Pubitemid 38786565)
19. Wydmanski J. Study of effectiveness and tolerance of preand postoperative radiochemotherapy for patients with stomach cancer. Nowotwory J Oncol 2008;58:5-47.
20. Ocheduszko S, Chlosta M, Pawlega J. The efficacy and tolerance of adjuvant chemoradiotherapy in gastric cancer - a preliminary report. Nowotwory J Oncol 2008;58:413-17.
21. Leong T, Willis D, Joon DL, Condron S, Hui A, Ngan SY. 3D Conformal radiotherapy for gastric cancer - results of a comparative planning study. Radiother Oncol 2005;74:301-6. (Pubitemid 40349140)
22. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-9. (Pubitemid 26112171)
23. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-8.
24. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Italian Research Group for Gastric Cancer (IRGGC). Ann Surg 2007;245:543-52.
25. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease - specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-50. (Pubitemid 46594058)
26. Valentini V, Cellini F, Minsky BD, Mattiucci GC, Balducci M, D'Agostino G, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 2009;92:176-83.
27. Fiorica F, Cartei F, Enea M, Licata A, Cabibbo G, Carau B, et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007;33:729-40. (Pubitemid 350082668)
28. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophagal cancer. N Engl J Med 2006;355:11-20.
29. Jackson C, Cunningham D, Oliveira J; ESMO Guidelines Working Group. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:34-6.